Paper Details

  1. Home
  2. Paper Details

A comparative study of clarithromycin modified release and amoxicillin/clavulanic acid in the treatment of acute exacerbation of chronic bronchitis.

Author: , BauerK, CarrW D, CullenS, Heredia BudoJ L, MacLeodC, MartinotJ B, SanguinettiC M, van VeldhuizenW C

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study compared the efficacy and tolerability of clarithromycin modified release (MR) with amoxicillin/clavulanic acid in patients with acute exacerbation of chronic bronchitis. Both treatments were found to be effective, but clarithromycin was associated with fewer side effects and higher compliance rates.
Paper Details　
Original Abstract of the Article :
This phase III, investigator-blind, randomized, parallel-group study compared the efficacy and tolerability of clarithromycin modified release (MR) with those of amoxicillin/clavulanic acid in 250 adult outpatients with acute exacerbationof chronic bronchitis (AECB). Patients received either clarith...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/BF02850246

データ提供：米国国立医学図書館（NLM）

Comparing Clarithromycin Modified Release and Amoxicillin/Clavulanic Acid for Acute Exacerbation of Chronic Bronchitis

This research presents a head-to-head comparison of two commonly used antibiotics, [clarithromycin modified release (MR)] and [amoxicillin/clavulanic acid], in treating [acute exacerbation of chronic bronchitis (AECB)]. The study, a [phase III, investigator-blind, randomized, parallel-group study], involved [250 adult outpatients] with [AECB], who were randomly assigned to receive either clarithromycin MR or amoxicillin/clavulanic acid for [7 days]. The primary endpoints were [sponsor-defined clinical response] and [pathogen outcome] at the end of treatment. The findings demonstrate that both treatments were [statistically equivalent] in terms of [efficacy and tolerability], with [clarithromycin MR] producing [fewer side effects] and [discontinuations] and achieving [higher compliance rates].

Clarithromycin MR: A Potentially Better Choice for AECB Treatment

The research suggests that clarithromycin MR may be a more favorable treatment option for AECB due to its [better tolerability] and [improved compliance rates]. This finding is clinically significant, as it could lead to [improved patient satisfaction] and potentially [better treatment outcomes]. While both clarithromycin MR and amoxicillin/clavulanic acid were effective in treating AECB, the lower incidence of side effects and higher compliance associated with clarithromycin MR make it a potentially superior choice for managing this condition.

AECB: Finding the Right Treatment for a Persistent Cough

Acute exacerbation of chronic bronchitis can be a frustrating and uncomfortable experience. This research suggests that clarithromycin MR may offer a more tolerable and effective treatment option compared to amoxicillin/clavulanic acid. If you are experiencing symptoms of AECB, consulting with your physician to discuss the most suitable treatment for your individual needs is important. Remember, each person responds differently to medications, and finding the right treatment can significantly improve your quality of life.

Dr. Camel's Conclusion

This study, like a soothing balm for a persistent cough, highlights the importance of choosing the right treatment for AECB. Clarithromycin MR emerges as a potential winner in this battle against bronchitis, offering fewer side effects and improved compliance. It's a reminder that even in the vast desert of medical options, finding the right treatment can make a significant difference in managing your health.

Date :
  1. Date Completed 2001-09-06
  2. Date Revised 2019-11-05
Further Info :

Pubmed ID

11512528

DOI: Digital Object Identifier

10.1007/BF02850246

Related Literature

Article Analysis
・Side Effects of amoxicillin and clavulanic acid
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.